


REGIONAL IMMUNOSUPPRESSION FOR CORNEAL TRANSPLANTATION

SARAH L BRICE

B. Biotech (Hons)



Thesis submitted for the degree of

Doctor of Philosophy

January 2010

Faculty of Health Sciences

School of Medicine

Flinders University of SA

Adelaide, Australia

TABLE OF CONTENTS

ABSTRACT	x
CONFERENCE PRESENTATIONS ARISING FROM THIS THESIS	xiii
DECLARATION.....	xiv
ACKNOWLEDGEMENTS	xv
ABBREVIATIONS	xvii
CHAPTER 1: INTRODUCTION.....	1
1.1 INTRODUCTION OVERVIEW	2
1.2 THE HUMAN CORNEA.....	2
1.2.a. Anatomy of the human cornea.....	2
1.2.b. Proliferative capacity of the human corneal endothelium.....	4
1.3. CORNEAL TRANSPLANTATION.....	5
1.4 ANIMAL MODELS OF CORNEAL TRANSPLANTATION	7
1.5 MECHANISMS OF CORNEAL GRAFT REJECTION	8
1.6 IMMUNOLOGY OF CORNEAL TRANSPLANTATION	9
1.6.a. T cells	9
1.6.b. Antigen presenting cells (APCs) in the eye.....	13
1.6.c. Allorecognition.....	20
1.6.d. Ocular lymphatic drainage	21
1.6.e. Immune privilege in the eye	27
1.7 THERAPIES FOR CORNEAL GRAFT REJECTION	29
1.7.a. Topical application of glucocorticosteroids	29
1.7.b. HLA-matching.....	29
1.7.c. Systemic immunosuppression using calcineurin blockers	30
1.7.d. Antibodies and antibody fragments.....	30

1.8 GENE THERAPY	34
1.8.a. Gene therapy overview	34
1.8.b. Gene transfer to the corneal endothelium.....	35
1.8.c. Lentivirus biology.....	37
1.8.d. Recombinant lentiviral vectors for gene transfer	38
1.8.e. The Anson HIV-1 vector system	44
1.9 BIOSAFETY ISSUES ASSOCIATED WITH GENE THERAPY	46
1.9.a. The first gene therapy death	46
1.9.b. Insertional mutagenesis	47
1.9.c. Immune reactivity of viral vectors.....	48
1.9.d. Gene therapy for the treatment of non-life threatening disease	48
1.9.e. Ocular gene therapy	49
1.9.f. Summary of the biosafety issues associated with gene therapy.....	49
1.10 SUMMARY AND AIMS.....	50
CHAPTER 2: MATERIALS AND METHODS	53
2.1 MATERIALS	54
2.1.a. General chemicals.....	54
2.1.b. Antibodies	54
2.1.c. Antibody fragments	54
2.1.d. Antibiotics	54
2.1.e. <i>Escherichia coli</i> (<i>E. coli</i>) strains.....	56
2.1.f. Plasmids	56
2.1.g. Molecular biology reagents	56
2.1.h. Polymerase chain reaction (PCR) primers	56
2.1.i. Mammalian cell culture reagents	56

2.1.j. Animals	61
2.1.k. Miscellaneous reagents.....	61
2.1.l. Filter cube specifications on fluorescence microscopes	61
2.2 MOLECULAR METHODS	63
2.2.a. Plasmid DNA preparation	63
2.2.b. Restriction endonuclease digestion	64
2.2.c. Dephosphorylation with shrimp alkaline phosphatase (SAP)	64
2.2.d. Purification of digested and/or SAP-treated DNA	65
2.2.e. Ligations	65
2.2.f. Purification of ligation products	65
2.2.g. Agarose gel electrophoresis.....	66
2.2.h. Preparation of electrocompetent cells (<i>E. coli</i> strains).....	66
2.2.i. Electroporation of <i>E. coli</i> strains DH5 α and GM48.....	67
2.2.j. End-point polymerase chain reaction (PCR).....	68
2.2.k. Total RNA extraction	69
2.2.l. DNase I treatment of RNA.....	70
2.2.m. cDNA synthesis.....	71
2.3 QUANTITATIVE REAL-TIME PCR (QPCR)	71
2.3.a. Primers for qPCR.....	71
2.3.b. qPCR set up.....	72
2.3.c. Determination of primer pair amplification efficiency.....	73
2.3.d. Gene expression analysis.....	73
2.4 CELL CULTURE METHODS	74
2.4.a. Maintenance of cell lines.....	74
Table 2.9: Cell lines.....	75

2.4.b. Freezing cell lines.....	75
2.4.c. Thawing cells.....	75
2.4.d. Cell viability determinations	76
2.4.e. Liposome-mediated transfection of mammalian cells.....	76
2.4.f. Transduction of mammalian cells with lentiviral vectors	77
2.4.g. Flow cytometry to detect scFv binding	77
2.4.h. Flow cytometry for eYFP detection in transfected or transduced cells	79
2.4.i. Fluorescence microscopy of cell lines	80
2.4.j. Human endostatin::kringle-5 (EK5) detection in culture supernatant by ELISA.....	80
2.4.k. Determination of endotoxin levels in viral preparations	80
2.5 LENTIVIRAL VECTOR PRODUCTION AND TESTING	81
2.5.a. Large scale lentiviral vector preparations.....	81
2.5.b. Medium scale lentiviral vector preparations	83
2.5.c. Detection of replication-competent lentivirus	84
2.5.d. Titration of lentiviral vector preparations	84
2.6 ADENOVIRAL VECTOR PREPARATION	87
2.6.a. Adenoviral vector production.....	87
2.6.b. Titration of adenoviral vector preparations	89
2.7 ANIMAL AND TISSUE METHODS	90
2.7.a. Conventional histology.....	90
2.7.b. Nuclear staining of tissues.....	90
2.7.c. Fluorescence microscopy of rat tissues	91
2.7.d. Transduction of rat tissues with viral vectors.....	92
2.7.e. Rat orthotopic corneal transplantation.....	94

2.7.f. Post-operative assessment of corneal grafts.....	95
2.7.g. Collection of rat blood by tail tipping	97
2.7.h. Lymphadenectomy of cervical lymph nodes.....	97
2.8 STATISTICAL ANALYSIS	98
2.8.a. Statistical analysis of transgene expression.....	98
2.8.b. Statistical analysis of corneal graft survival and inflammation data.....	98
CHAPTER 3: CONSTRUCTION AND CHARACTERISATION	
OF LENTIVIRAL VECTORS	99
3.1 ABSTRACT	100
3.2 INTRODUCTION.....	101
3.2.a. Gene transfer to the eye	101
3.2.b. Lentiviral vectors for gene transfer	101
3.2.c. CD4 as a target for T cell activation.....	102
3.2.d. ScFv as a potential treatment to the cornea.....	102
3.2.e. The Foot and Mouth Disease Virus (FMDV) 2A self-processing sequence	103
3.2.f. Specific aims	103
3.3 RESULTS.....	104
3.3.a. Construction of lentiviral plasmids.....	104
3.3.b. Analysis of lentiviral vector titration.....	123
3.3.c. Transgene expression from single-gene and dual-gene vectors	128
3.4: SUMMARY AND DISCUSSION	139
3.4.a. Summary.....	139
3.4.b. Titration of lentiviral vector preparations	140
3.4.c. Multigenic expression using the 2A self-processing sequence	146

CHAPTER 4: EXPRESSION OF ANTI-RAT CD4 SCFV AT POTENTIAL SITES OF ANTIGEN PRESENTATION.....	154
4.1 ABSTRACT	155
4.2 INTRODUCTION.....	156
4.2.a. Corneal graft rejection.....	156
4.2.b. Regional immunosuppression	156
4.2.c. Anti-rat CD4 scFv as an immunosuppressive agent.....	158
4.2.d. Specific aims	159
4.3 RESULTS.....	160
4.3.a Lentiviral transduction of the corneal endothelium.....	160
4.3.b. Lentiviral transduction of the cervical lymph nodes	182
4.3.c. Bilateral lymphadenectomy of the cervical lymph nodes	185
4.4 SUMMARY AND DISCUSSION	189
4.4.a. Summary.....	189
4.4.b. Immunosuppression produced by the corneal endothelium.....	192
4.4.c. Immunosuppression within the anterior segment.....	195
4.4.d. Immunosuppression within the cervical lymph nodes	198
4.4.e. Regional immunosuppression for corneal transplantation in the rat	201
CHAPTER 5: FINAL DISCUSSION.....	203
5.1 SUMMARY OF THE MAJOR FINDINGS FROM THIS THESIS	204
5.2 MULTI-GENE EXPRESSION USING THE 2A SELF-PROCESSING SEQUENCE	205
5.2.a. Expression of multiple transgenes from a single lentiviral construct.....	205
5.2.b. Stoichiometry of upstream and downstream proteins expressed from 2A vectors	207

5.2.c. The use of the 2A self-processing sequence to prevent corneal allograft rejection	210
5.3 ANTIGEN PRESENTATION DURING CORNEAL TRANSPLANTATION.	211
5.3.a. Antigen travels from the eye to the secondary lymphoid organs in soluble form	211
5.3.b. Evidence for antigen presentation within the anterior segment of the eye .	215
5.3.c. A proposed model of antigen presentation during corneal transplantation in rodents	217
5.3.d. Inhibition of antigen presentation with anti-CD4 antibodies and antibody fragments in rodents	222
5.3.e. The outcome of corneal allograft survival after bilateral lymphadenectomy of the cervical lymph nodes in rodents	224
5.3.f. Regional immunosuppression for human corneal transplantation.....	228
APPENDIX 1: BUFFERS AND SOLUTIONS	230
A1.1 Chrome-alum-subbed microscope slides.....	231
A1.2 DEPC-H ₂ O	231
A1.3 DMEM (high glucose).....	231
A1.4 Eosin stain	231
A1.5 FACS fixative	232
A1.6 GelRed TM agarose plates	232
A1.7 Haematoxylin solution.....	232
A1.8 HEPES-buffered RPMI medium	233
A1.9 HEPES-buffered Saline	233
A1.10 LB medium	233
A1.11 LB agar plates	234

A1.12 Low salt LB medium	234
A1.13 PBS (10x)	234
A1.14 PBS-azide	235
A1.15 RBC lysis solution (10X)	235
A1.16 SOC medium	235
A1.17 Sodium azide 4M stock	235
A1.18 TBE (10x)	236
A1.19 Trypan blue stock	236
A1.20 Trypsin-EDTA	236
APPENDIX 2: VECTOR MAPS	237
A2.1: pBS-CD55-F2A-CD59 vector map	238
A2.2: pHIV-eYFP vector map	239
A2.3 fHSSOX38scFv in pAdtrackCMV vector map	240
A2.4 pHIV-EK5 vector map	241
A2.5 pBLAST41-hEndoKring5 vector map	242
APPENDIX 3: CONSTRUCTION OF pHIV-CD4scFv	243
APPENDIX 4: SEQUENCE ANALYSIS	251
A4.1 Sequence analysis of pHIV-CD4scFv_F2A_eYFP	253
A4.2 Sequence analysis of pHIV-eYFP_F2A_CD4scFv	255
A4.3 Sequence analysis of pHIV-CD4scFv_F2A	257
A4.4 Sequence analysis of pHIV-CD4scFv_F2A_EK5	259
REFERENCES	251

ABSTRACT

Corneal transplantation is performed to restore vision or to relieve pain in patients with damaged or diseased corneas. However, approximately 40% of corneal allografts fail after 10 years. The most common cause of graft failure is irreversible immunological rejection, primarily mediated by CD4⁺ T cells, despite the topical application of glucocorticosteroids. The aim of this project was to investigate the anatomic site of antigen presentation during corneal transplantation in the rat, by using a lentiviral vector to express an anti-CD4 antibody fragment at potential sites of antigen presentation, including the donor corneal endothelium, the anterior segment of the eye and the cervical lymph nodes.

Dual-gene lentiviral vectors were constructed by inserting the 2A self-processing sequence between two transgenes. This allowed expression of two transgenes within a single open reading frame. *In vitro* characterisation of the dual-gene vectors was performed in cell culture experiments, which showed that transgenic proteins were expressed at lower levels from dual-gene vectors compared to the expression from single-gene vectors and expression was lowest when the transgene was situated downstream of the 2A self-processing sequence.

To locate the anatomic site of antigen presentation during corneal transplantation in rats, a lentiviral vector carrying an anti-CD4 antibody fragment was delivered to the corneal endothelium either immediately prior to corneal transplantation by *ex vivo* transduction of the donor corneas, or 5 days prior to corneal transplantation by anterior chamber injection into both the recipient and the donor rats. A separate group of recipient rats received intranodal injections of the lentiviral vector carrying

an anti-CD4 antibody fragment into the cervical lymph nodes 2 days prior to corneal transplantation. Another group of rats underwent bilateral lymphadenectomy of the cervical lymph nodes 7 days prior to corneal transplantation. Corneal allografts were scored daily for opacity, inflammation and neovascularisation. Expression of the anti-CD4 antibody fragment from transduced tissues was detected using flow cytometry and polymerase chain reaction. Modest, but significant prolongation of corneal allograft survival was experienced by rats that received *ex vivo* transduction of the donor corneas with a lentiviral vector carrying an anti-CD4 antibody fragment immediately prior to corneal transplantation, but all grafts did eventually reject. Anterior chamber injection of the lentiviral vector carrying the anti-CD4 antibody fragment 5 days prior to corneal transplantation into both recipient and donor eyes did not prolong allograft survival. Intranodal injection of a lentiviral vector carrying an anti-CD4 antibody fragment did not prolong the survival of the corneal allografts, nor did bilateral lymphadenectomy of the cervical lymph nodes 7 days prior to corneal transplantation.

Neither expression of the anti-CD4 antibody fragment in the cervical lymph nodes nor the removal of these nodes was able to prolong corneal allograft survival in rats, suggesting that T cell sensitisation could potentially occur elsewhere in the body. However, expression of the anti-CD4 antibody fragment from the donor corneal endothelium was able to prolong corneal allograft survival, suggesting that some antigen presentation might occur within the anterior segment of the eye. Based on the findings described in this thesis and those of others, I propose that antigen presentation in the rat occurs within anterior segment of the eye and within the secondary lymphoid tissues such as the cervical lymph nodes, and that inhibiting

antigen presentation at one of these sites will delay graft rejection. However, to completely abolish antigen presentation during corneal transplantation in the rat, I hypothesise that antigen presentation within both the anterior segment of the eye and within the secondary lymphoid tissues must be inhibited.

CONFERENCE PRESENTATIONS ARISING FROM THIS THESIS

Brice S.L., Mortimer L.M., Marshall K.A., Brereton H.M., Williams K.A. Lentiviral-mediated gene transfer of anti-CD4 scFv prolongs corneal allograft survival. 2009 May 29-April 1, Australian Gene Therapy Society meeting, Sydney, poster presentation.

Brice S.L., Mortimer L.M., Brereton H.M., Williams K.A. Lentiviral gene transfer to the rat cornea. 2008 August 9-14, The Transplantation Society – XXII International Congress, Sydney, poster presentation.

DECLARATION

I certify that this thesis does not incorporate without acknowledgement any material previously submitted for a degree or diploma in any university; and that to the best of my knowledge and belief it does not contain any material previously published or written by another person except where due reference is made in the text.

Sarah L Brice

ACKNOWLEDGEMENTS

This project would not have been possible without the technical assistance provided by the following people:

- Kirsty Kirk who performed all the rat corneal grafts and histology for this project.
- The staff of the Gene Technology Unit at the Women's and Children's Hospital, including Donald Anson, Stanley Tan and Sue Ping Lim for their assistance with lentivirus production.
- Lauren Mortimer for setting up lentiviral titration and RCR assays at Flinders.
- Yazad Irani who assisted with the cloning of one of the vectors used in this project.

I would like to thank my principal supervisor Keryn Williams for taking me on as a student. Keryn, I feel privileged to have had the opportunity to learn from you. It took a while, but thanks to your persistence, I feel more able to critically analyse both my own work, and the work of others.

I would also like to thank Helen Brereton for her supervision and guidance throughout my project. Helen, your knowledge of cloning and molecular biology has been an invaluable resource for my project.

I would like to especially mention Kirsty Kirk who performed all of the corneal grafts and histology for my project. Kirsty, your technical prowess was truly phenomenal, even while wearing your "Darth Vader" mask. I will miss your infectious, bubbly personality.

I would like to thank Lauren Mortimer for all the long days she has put in with virus production, titration and associated procedures. Lauren, I have been very grateful for your meticulous problem solving abilities and dedication to your work. We have been studying and working together for such a long time now, I am really going to miss you as a colleague and a friend.

I would also like to thank the entire Department of Ophthalmology at Flinders University for being an inviting, helpful and friendly group of people to work with. Thank you to Alison, Dave, Kath, Yazad, Sonja, Margaret, Mel, Shiwani, Sarah and Paul for our team room discussions and for being more than just work colleagues and becoming real friends.

To Claire Jessup, thank you for taking me under your wing, mentoring me through the early stages of my project and providing me with a house to live in. I would also like to thank Melinda Tea for being a wonderful house mate, PhD buddy and supportive friend. I really will miss working and living with you.

To my friends Susan, Lisa, Row, Helen, Michelle, Loretta and Jelena, thank you for being there for me when I needed to some non-thesis time. I look forward to seeing a lot more of you now. I would like to acknowledge my godparents Auntie Sue and Uncle Kent, for showing a real interest in my studies and to my brother Nathaniel, thank you for always being only a phone call away despite the distance between us. I would like to thank Oscar my beautiful cat, for all the cuddles and affection when I needed it.

I would like to thank my parents for encouraging me to be the best I can be, for installing the drive in me to never give up and to always finish what I start. Thank you to Richie, for loving and caring for me even through my crazy moments and for looking after me when I wasn't even looking after myself. Your support has meant the world to me.

Lastly, I would like to dedicate this thesis to my grandparents who have always believed in me. You have been my inspiration and Grandpa I wish you were able to see the final product.

ABBREVIATIONS

>	greater than
<	less than
°C	degrees Celsius
µg	microgram
µl	microlitre
µm	micrometre
A549	human lung adenocarcinoma epithelial cell line
AAV	adeno-associated viral vector
AC	anterior chamber
ACAID	anterior chamber-associated immune deviation
Adv	adenoviral vector
AE	amplification efficiency
Ag	antigen
AIDS	acquired immunodeficiency syndrome
APC	antigen presenting cell
ARBP	acidic ribosomal phosphoprotein
bp	base pair
BSS	balanced salt solution
CaCl ₂	calcium chloride
CALT	conjunctiva-associated lymphoid tissue
CB-Dx	cascade blue dextran
CCTS	The American Collaborative Corneal Transplant Study
CH	constant domain of immunoglobulin heavy chain
CHO	Chinese hamster ovarian cell line

CD	cluster of differentiation
CD40L	CD40 ligand
cDNA	complementary deoxyribonucleic acid
CGD	chronic granulomatous disease
CL	constant domain of immunoglobulin light chain
CLN	cervical lymph node
cm	centimetre
CMV	cytomegalovirus immediate early promoter
CPE	cytopathic effects
cPPT	central polypurine tract
CT	cycle threshold
CTL	cytotoxic T lymphocyte
CTLA-4	cytotoxic T lymphocyte-associated protein-4 (CD152)
Da	Dalton
DC	dendritic cell
DDH ₂ O	double distilled water
DEPC	diethylpyrocarbonate
DMEM	Dulbecco's Modified Eagle Medium
DMSO	dimethyl sulphoxide
DNA	deoxyribonucleic acid
dNTP	dinucleotide triphosphate
ds	double stranded
DTH	delayed type hypersensitivity
DTT	dithiothreitol
eGFP	enhanced green fluorescent protein

eYFP	enhanced yellow fluorescent protein
ECACC	European Collection of Cell Cultures
<i>E. Coli</i>	<i>Escherichia coli</i>
EK5	human endostatin::kringle-5 fusion protein
ELISA	enzyme-linked immunosorbent assay
ETDA	ethylene diamine tetra acetic acid
EU	endotoxin unit
F2A	FMDV 2A self-processing sequence with a furin cleavage site immediately upstream of 2A, and a 2B proline residue at its C-terminus
F344	Fisher 344 inbred rat strain
Fab	monomeric antigen binding fragment
FACS	fluorescence-activated cell sorting
FasL	Fas-ligand (CD95L)
Fc	crystallisable fragment
FCS	fetal calf serum
FDA	Food and Drug Administration
fHSS	factor H secretory sequence
FITC	fluorescein isothiocyanate
FMDV	foot and mouth disease virus
g	gram
g	unit of gravity
gDNA	genomic deoxyribonucleic acid
GFP	green fluorescent protein
HeBS	HEPES-buffered saline

HEK-293A	human embryonic kidney cell line with E1- region of adenovirus 5
HEK-293T	human embryonic kidney cell line that constitutively expresses the SV40 large T cell antigen
HEPES	N-2-hydroxyethylpiperazine-N-2-ethanesulphonic acid
HIS6 tag	6 histidine tag
HIV	human immunodeficiency virus
HLA	human leucocyte antigen
HRP	horseradish peroxidase
HPRT	hypoxanthine guanine phosphoribosyl-transferase
Hz	Hertz
IFN- γ	interferon gamma
Ig	immunoglobulin
IL	interleukin
IRES	internal ribosome entry sites
IU/ml	international units/ml
kb	kilobase
kDa	kilodalton
L	litre
LB	luria bertani
LC	Langerhans cells
LCA2	Leber's congenital amaurosis type 2
LIP	liposome-incorporated
log	logarithm
log _e	natural logarithm
LTR	long terminal repeat

LV	lentiviral vector
LYVE-1	lymphatic vessel endothelial hyaluronan receptor 1
M	Molar
mAb	monoclonal antibody
MLN	mesenteric lymph node
MFI	mean fluorescence intensity
mg	milligram
MHC	major histocompatibility complex
ml	millilitre
MLR	mixed lymphocyte reaction
MLV	Molony murine leukaemia viral vector
mm	millimetre
MOI	multiplicity of infection
mRNA	messenger ribonucleic acid
MW	molecular weight
NIH	National Institutes of Health
ng	nanogram
NHMRC	National Health and Medical Research Council
NK	natural killer cell
NTC	no template control
OD	optical density
ORF	open reading frame
OVA	ovalbumin peptide
pA	polyadenylation signal
PBL	peripheral blood lymphocytes

PBS	phosphate buffered saline
PC2	physical containment level 2
PCR	polymerase chain reaction
PE	phycoerythrin
pfu	plaque forming unit
pg	pictogram
PGK	phosphoglycerate kinase
pmol	picomole
polyA	polyadenylation site
PPT	polypurine tract
qPCR	quantitative real-time polymerase chain reaction
qRT-PCR	quantitative reverse transcription real-time polymerase chain reaction
RBC	red blood cells
RCR	replication competent recombinant
RNA	ribonucleic acid
RPMI	Roswell Park Memorial Institute
RRE	rev response element
RRExt	extended rev response element
RT	reverse transcription
SAP	shrimp alkaline phosphatase
SAPE	streptavidin R-phycoerythrin
SCID-X1	x-linked severe combined immunodeficiency disorder
scFv	single chain fragment variable
SD	standard deviation
sFlt-1	soluble vascular endothelial growth factor receptor 1

SIN	self inactivating
SOC	Super Optimal Broth with 20 mM glucose. 'C' stands for catabolite repression, reflective of the added glucose.
SOE-PCR	splice overlap extension polymerase chain reaction
ss	single stranded
SV40	simian-like virus type-40 early promoter
Tc	cytotoxic response
TCID ₅₀	tissue culture infectious dose method
TCR	T cell receptor
TGF- β	transforming growth factor beta
Th	T helper response
T _m	melting temperature
TNF	tumour necrosis factor
TU	transducing units
UV light	ultraviolet light
v/v	volume per volume
VEGF	vascular endothelial growth factor
VEGFR	vascular endothelial growth factor receptor
VH	variable domain of immunoglobulin heavy chain
VL	variable domain of immunoglobulin light chain
VSV	vesicular stomatitis virus
VSV-G	vesicular stomatitis virus glycoprotein G
whv	woodchuck hepatitis virus post-transcriptional element
w/v	weight per volume
WF	Wistar Furth inbred rat strain

WT wild type